Rheumatology International is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases.
It serves an international, interdisciplinary group of workers involved in problems of rheumatic diseases. Coverage includes the management of rheumatic diseases, and extends to all modern trends in clinical research. Contributions include original publications, short communications, editorials, letters to the editors and reviews. No case reports will be accepted.

  • An independent journal reporting on worldwide research, diagnosis and management of rheumatic diseases
  • Covers disease management as well as trends in clinical research
  • Presents original research, editorials, letters and reviews
  • Average time from submission to 1st decision: 21 days
  • 97% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again

Journal information

Editor-in-Chief
  • Armen Yuri Gasparyan
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

2.631 (2020)
Impact factor
2.686 (2020)
Five year impact factor
20 days
Submission to first decision
59 days
Submission to acceptance
514,203 (2020)
Downloads

Latest articles

Journal updates

  • New and increased Impact Factor for Rheumatology International

    We are delighted to announce that Rheumatology International's 2020 Impact Factor is 2.631. Our Immediacy Index (average number of times an article is cited in the year it is published) has also increased from 0.568 to 1.236. Thank you to all our authors, reviewers and Editors who have made such valuable contributions to the journal!

    New Content Item
  • Celebrating editorial excellence

    Congratulations to Dr Armen Gasparyan and his editorial team! Rheumatology International is a top rated Springer Nature journal, based on data collected from the Journal Author Satisfaction Survey. We're recognising extraordinary editors for their commitment and passion to their journals. Learn more about editorial excellence.

    New Content Item (1)
  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

About this journal

Electronic ISSN
1437-160X
Abstracted and indexed in
  1. ANVUR
  2. BFI List
  3. BIOSIS
  4. Biological Abstracts
  5. CAB Abstracts
  6. CLOCKSS
  7. CNKI
  8. CNPIEC
  9. Chemical Abstracts Service (CAS)
  10. Current Contents/ Life Sciences
  11. Current Contents/Clinical Medicine
  12. Dimensions
  13. EBSCO Academic Search
  14. EBSCO Biomedical Reference Collection
  15. EBSCO Discovery Service
  16. EBSCO STM Source
  17. EMBASE
  18. Google Scholar
  19. Japanese Science and Technology Agency (JST)
  20. Journal Citation Reports/Science Edition
  21. Medline
  22. Naver
  23. OCLC WorldCat Discovery Service
  24. Pathway Studio
  25. Portico
  26. ProQuest-ExLibris Primo
  27. ProQuest-ExLibris Summon
  28. Reaxys
  29. SCImago
  30. SCOPUS
  31. Science Citation Index
  32. Science Citation Index Expanded (SciSearch)
  33. Semantic Scholar
  34. TD Net Discovery Service
  35. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer-Verlag GmbH Germany, part of Springer Nature